This site is intended for healthcare professionals

FDA approves PD-L1 IHC 22C3 pharmDx as aid in identifying triple-negative breast cancer.- Agilent Technologies

Read time: 1 mins
Last updated:15th Nov 2020
Published:15th Nov 2020
Condition: Breast Cancer Triple Neg
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest